|Over a quarter ago|
One new option listing and six option delistings on July 22nd » 08:3007/2207/22/19
SLRX, FLKS, IHG, NBSE, PKD, PULM, SVA
New option listings for…
New option listings for July 22nd include Salarius Pharmaceuticals Inc (SLRX). Option delistings effective July 22nd include Flex Pharma Inc (FLKS), InterContinental (IHG), NeuBase Therapeutics Inc (NBSE), Parker Drilling (PKD), Pulmatrix (PULM), and Sinovac Biotech (SVA).
Salarius Pharmaceuticals closes strategic merger with Flex Pharma » 08:1707/2207/22/19
Salarius Pharmaceuticals (SLRX) announced that Salarius Pharmaceuticals has closed its merger with Flex Pharma (FLKS) wholly owned subsidiary on July 19, 2019. Flex Pharma, Inc. has been renamed and will operate as Salarius Pharmaceuticals, Inc. The newly combined company will focus on the continued development of Salarius' clinical pipeline, which targets rare, orphan cancers for which no approved targeted treatments are currently available and cancers with a high unmet need. The company will be led by Salarius' current management team under the leadership of President and CEO, David Arthur. Former Flex Pharma President and CEO, William McVicar, Ph.D., will join Salarius' Board of Directors. The company's common stock will trade on the Nasdaq Capital Market under the new ticker symbol "SLRX" beginning on July 22, 2019 and will reflect the previously announced 25:1 reverse stock split that occurred effective as of the close of business on July 19, 2019. Salarius' lead compound, Seclidemstat, targets the epigenetic dysregulation underlying Ewing sarcoma, a devastating pediatric, adolescent, and young adult bone and soft-tissue cancer for which no approved targeted therapies are currently available. Seclidemstat is a differentiated, reversible inhibitor of lysine-specific demethylase 1, or LSD1, which is a widely studied epigenetic enzyme and a validated drug target for clinical development. Salarius is currently enrolling refractory and relapsed Ewing sarcoma patients in an open-label Phase 1 dose escalation/dose expansion study, with potential early cohort data readouts in 2020. Salarius is also conducting a Phase 1 clinical study of Seclidemstat in patients with advanced solid tumors including, but not limited to, prostate, breast, and ovarian cancers.
Flex Pharma shareholders approve all proposals relating to Salarius merger » 16:0607/1207/12/19
Flex Pharma announced…
Flex Pharma announced that its stockholders approved all proposals relating to its planned merger with Salarius Pharmaceuticals at Flex Pharma's special meeting of stockholders. Flex Pharma will file a Form 8-K to disclose detailed voting results for each proposal. Flex Pharma expects to complete the merger within the next week or two.
Flex Pharma announces ISS, Glass Lewis recommend shareholders vote for agenda » 07:0506/1006/10/19
Flex Pharma announced…
Flex Pharma announced that Institutional Shareholder Services, or ISS, and Glass Lewis recommend that shareholders vote for all agenda items before or at Flex Pharma's June 14 special shareholders meeting. Flex's board also unanimously recommends voting for all agenda items as the best way to preserve future shareholder value. Salarius Pharmaceuticals is a privately held clinical-stage oncology company targeting the epigenetic causes of cancers. ISS said, "The proposed transaction with Salarius appears to offer FLKS shareholders a better potential outcome than FLKS' standalone business. The Flex board also ran a reasonably thorough sale process before identifying this transaction as the best available option. The company contacted or was contacted by 184 parties to solicit interest and the company received proposals from 26 parties. The reverse stock split is necessary to avoid delisting of the company's common stock from the Nasdaq Capital Market. As such, support for this proposal is warranted. In light of the upside potential for Salarius' leading drug candidate, the reasonably thorough sale process used to evaluate alternative options, the positive market reaction, and the downside risk of rejecting this proposal and continuing with FLKS' standalone business plan, support for this proposal is warranted."